HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC trade dress

This article was originally published in The Rose Sheet

Executive Summary

CTFA supports FDA's technical amendment to OTC labeling rule, which loosens trade dress guidelines and allows use of dark-on-light and light-on-dark type. "The amended version of the final rule provides appropriate recognition of the value of trade dress" for manufacturers and consumers, the trade group says in March 17 comments. In previous verbal and written arguments, CTFA maintained that as originally drafted, the reg would restrict product distinctiveness. FDA granted the amendment in January (1"The Rose Sheet" Jan. 10, p. 9)

You may also be interested in...



OTC Labeling Trade Dress Issue Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label reform rule published in the Jan. 3 Federal Register.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS007848

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel